AVXL - Company ID 0001314052
The table below shows ANAVEX LIFE SCIENCES CORP.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$39.04M | -$30.81M | -$27.79M | -$24.24M | -$30.38M | -$21.29M |
| Capital expenditure | - | - | - | - | - | - |
| Investing cash flow | - | - | - | - | - | - |
| Dividends paid | - | - | - | - | - | - |
ANAVEX LIFE SCIENCES CORP. reported operating cash flow of -$39.04M for fiscal year 2025. That is down 26.7% from -$30.81M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$9.24M (FY 2016) to -$39.04M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $9.43M | $11.97M | $29.65M | $21.29M | $153.24M | $28.35M |